Biogen Completes Acquisition of Human Immunology Biosciences
Global Newswire by Notified: M&A
JULY 2, 2024
Nasdaq: BIIB) has completed the acquisition of Human Immunology Biosciences (HI-Bioâ„¢), a privately-held clinical-stage biotechnology company focused on targeted therapies for patients with severe immune-mediated diseases (IMDs). CAMBRIDGE, Mass., July 02, 2024 (GLOBE NEWSWIRE) -- Biogen Inc.
Let's personalize your content